Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19
Status:
Terminated
Trial end date:
2020-06-19
Target enrollment:
Participant gender:
Summary
Background: There are no proven therapies specific for Covid-19. The full spectrum of
Covid-19 ranges from asymptomatic disease to mild respiratory tract illness to severe
pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The
efficacy of corticosteroids in viral ARDS remains controversial.
Methods: This is an internationally (Spain, Canada, China, USA) designed multicenter,
randomized, controlled, open-label clinical trial testing dexamethasone in mechanically
ventilated adult patients with established moderate-to-severe ARDS caused by confirmed
Covid-19 infection, admitted in a network of Spanish ICUs. Eligible patients will be randomly
assigned to receive either dexamethasone plus standard intensive care, or standard intensive
care alone. Patients in the dexamethasone group will receive an intravenous dose of 20 mg
once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10. The
primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free
days at 28 days. All analyses will be done according to the intention-to-treat principle.